The boss of Britain’s biggest pharmaceutical company has said the government’s recent drug pricing deal is a “very positive step” but is unlikely to unfreeze a paused £200m investment in Cambridge.
AstraZeneca’s chief executive, Pascal Soriot, suggested that a UK-US deal on NHS pricing agreed in December would not be “sufficient” to restart the project to build a research site in the east of England, which was paused in September.
Soriot, who has rebuilt the company’s drugs pipeline since 2012 and turned it into the UK’s most valuable listed busines
Continue Reading on The Guardian
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.